Literature DB >> 18848909

The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome.

Madhusudan Grover1, Hans Herfarth, Douglas A Drossman.   

Abstract

Gastroenterologists often encounter situations when the clinical and pathophysiological features that typically distinguish functional from organic disorders overlap. This "blurring of boundaries" can occur with post-infectious irritable bowel syndrome (PI-IBS), a subset of IBS and a newly described entity IBD-IBS. The key associating features include pain and usually diarrheal symptoms that are disproportionate to the observed pathology, microscopic inflammation, and often a co-association with psychological distress. A previous initiating gastrointestinal infection is required for PI-IBS and assumed for IBD-IBS. Using this perspective we discuss the clinical and pathophysiological features of PI-IBS and IBD-IBS and the growing evidence for the overlapping features of these two disorders in terms of alteration of gut flora, immune dysregulation, and role of stress. A unifying model of PI-IBS and IBD-IBS is proposed that may have important clinical and research implications. It obligates us to reframe our understanding of illness and disease from the dualistic biomedical model into a more integrated biopsychosocial (BPS) perspective.

Entities:  

Mesh:

Year:  2008        PMID: 18848909     DOI: 10.1016/j.cgh.2008.08.032

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  29 in total

1.  Durability of infliximab dose intensification in Crohn's disease.

Authors:  Kirk K Lin; Fernando Velayos; Elena Fisher; Jonathan P Terdiman
Journal:  Dig Dis Sci       Date:  2011-11-17       Impact factor: 3.199

2.  Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide Database.

Authors:  Edward L Barnes; Bharati Kochar; Millie D Long; Michael D Kappelman; Christopher F Martin; Joshua R Korzenik; Seth D Crockett
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

3.  Narcotic use for inflammatory bowel disease and risk factors during hospitalization.

Authors:  Millie D Long; Edward L Barnes; Hans H Herfarth; Douglas A Drossman
Journal:  Inflamm Bowel Dis       Date:  2011-07-07       Impact factor: 5.325

4.  Irritable bowel syndrome: a multidimensional disorder cannot be understood or treated from a unidimensional perspective.

Authors:  Ami D Sperber; Douglas A Drossman
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

5.  Estrogen modulation of visceral nociceptors.

Authors:  Victor Chaban
Journal:  Curr Trends Neurol       Date:  2013

Review 6.  Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

7.  Impact of pain on health-related quality of life in patients with inflammatory bowel disease.

Authors:  Anja Schirbel; Anne Reichert; Stephanie Roll; Daniel C Baumgart; Carsten Büning; Bianca Wittig; Bertram Wiedenmann; Axel Dignass; Andreas Sturm
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

8.  Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome.

Authors:  Anastassios C Manolakis; Andreas N Kapsoritakis; Panagiotis Georgoulias; Chara Tzavara; Varvara Valotassiou; Anastasia Kapsoritaki; Spyros P Potamianos
Journal:  BMC Gastroenterol       Date:  2010-10-14       Impact factor: 3.067

Review 9.  A role for corticotropin-releasing factor in functional gastrointestinal disorders.

Authors:  Yvette Taché; Cornelia Kiank; Andreas Stengel
Journal:  Curr Gastroenterol Rep       Date:  2009-08

Review 10.  Metabolomics as a diagnostic tool in gastroenterology.

Authors:  Vicky De Preter; Kristin Verbeke
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.